Once a target is identified the various effects of the drug can be measured. This involves all read-outs we use during the biomarker validation but instead of looking at the effect of various candidates we focus on one component.
As the tumor microenvironment can play an important role we focus especially on test methods involving fresh tissue.
Especially for preclinical research, we have established a comprehensive drug profiling platform, using our unique access to clinics, where drug candidates are tested on fresh tumor tissue slices or cells to predict the efficacy and absorption of drug compounds.
The compound effects can be measured regarding toxicity, pathway activity, and genomic and proteomic profiles. Multiplex IHC read-outs are done by in-house pathologists with state-of-the-art digital histopathology. Assays in characterized cell lines complement our offering.